Innoviva - INVA Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares.
View INVA analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 1 year target prices for Innoviva's stock. Their INVA share price forecasts range from $14.00 to $14.00. On average, they expect the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price.
View analysts price targets for INVA or view top-rated stocks among Wall Street analysts.

Innoviva's stock was trading at $17.25 at the beginning of the year. Since then, INVA stock has decreased by 20.9% and is now trading at $13.64.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our INVA earnings forecast.

Innoviva, Inc. (NASDAQ:INVA) posted its quarterly earnings data on Wednesday, November, 9th. The biotechnology company reported $0.60 earnings per share for the quarter, missing analysts' consensus estimates of $2.75 by $2.15. The biotechnology company had revenue of $67.26 million for the quarter, compared to the consensus estimate of $361.45 million. Innoviva had a trailing twelve-month return on equity of 23.89% and a net margin of 78.39%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Innoviva's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.61%), Vanguard Group Inc. (10.04%), Renaissance Technologies LLC (6.12%), Dimensional Fund Advisors LP (4.21%), LSV Asset Management (3.96%) and State Street Corp (3.54%). Insiders that own company stock include George Bickerstaff, Innoviva, Inc, Marianne Zhen and Plc Glaxosmithkline.
View institutional ownership trends.

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INVA stock can currently be purchased for approximately $13.64.

Innoviva (NASDAQ:INVA) has a market capitalization of $951.80 million and generates $391.87 million in revenue each year. The biotechnology company earns $265.85 million in net income (profit) each year or $3.19 on an earnings per share basis.

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The official website for the company is www.inva.com. The biotechnology company can be reached via phone at (650) 238-9600, via email at investor.relations@inva.com, or via fax at 650-827-8690.